Eyebright Medical Technology Beijing Co Ltd
SSE:688050
Income Statement
Earnings Waterfall
Eyebright Medical Technology Beijing Co Ltd
Revenue
|
713.4m
CNY
|
Cost of Revenue
|
-127.9m
CNY
|
Gross Profit
|
585.4m
CNY
|
Operating Expenses
|
-309.8m
CNY
|
Operating Income
|
275.6m
CNY
|
Other Expenses
|
-2.9m
CNY
|
Net Income
|
272.7m
CNY
|
Income Statement
Eyebright Medical Technology Beijing Co Ltd
Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||
Revenue |
182
N/A
|
273
+50%
|
331
+21%
|
376
+13%
|
416
+11%
|
433
+4%
|
480
+11%
|
500
+4%
|
549
+10%
|
579
+5%
|
638
+10%
|
713
+12%
|
|
Gross Profit | |||||||||||||
Cost of Revenue |
(29)
|
(44)
|
(58)
|
(68)
|
(75)
|
(68)
|
(81)
|
(83)
|
(89)
|
(88)
|
(111)
|
(128)
|
|
Gross Profit |
153
N/A
|
229
+50%
|
273
+19%
|
308
+13%
|
342
+11%
|
365
+7%
|
399
+9%
|
417
+4%
|
461
+11%
|
491
+7%
|
527
+7%
|
585
+11%
|
|
Operating Income | |||||||||||||
Operating Expenses |
(78)
|
(129)
|
(141)
|
(161)
|
(182)
|
(204)
|
(206)
|
(211)
|
(221)
|
(253)
|
(272)
|
(310)
|
|
Selling, General & Administrative |
(58)
|
(93)
|
(106)
|
(123)
|
(137)
|
(144)
|
(157)
|
(159)
|
(168)
|
(180)
|
(203)
|
(238)
|
|
Research & Development |
(16)
|
(23)
|
(34)
|
(40)
|
(48)
|
(43)
|
(54)
|
(58)
|
(59)
|
(54)
|
(74)
|
(81)
|
|
Depreciation & Amortization |
0
|
(14)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(22)
|
0
|
0
|
|
Other Operating Expenses |
(4)
|
2
|
(1)
|
2
|
2
|
0
|
5
|
6
|
6
|
3
|
5
|
9
|
|
Operating Income |
75
N/A
|
100
+33%
|
132
+32%
|
147
+11%
|
159
+8%
|
161
+1%
|
193
+20%
|
206
+7%
|
240
+16%
|
238
-1%
|
256
+7%
|
276
+8%
|
|
Pre-Tax Income | |||||||||||||
Interest Income Expense |
4
|
11
|
16
|
21
|
25
|
24
|
24
|
24
|
23
|
21
|
18
|
16
|
|
Non-Reccuring Items |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Total Other Income |
(0)
|
(0)
|
0
|
0
|
4
|
3
|
3
|
3
|
1
|
5
|
5
|
5
|
|
Pre-Tax Income |
79
N/A
|
111
+41%
|
149
+34%
|
168
+13%
|
188
+11%
|
188
+0%
|
221
+17%
|
233
+5%
|
264
+13%
|
264
+0%
|
278
+5%
|
297
+7%
|
|
Net Income | |||||||||||||
Tax Provision |
(11)
|
(15)
|
(19)
|
(18)
|
(21)
|
(20)
|
(32)
|
(35)
|
(41)
|
(37)
|
(31)
|
(31)
|
|
Income from Continuing Operations |
68
|
96
|
129
|
150
|
167
|
168
|
189
|
197
|
223
|
227
|
247
|
265
|
|
Income to Minority Interest |
0
|
0
|
(0)
|
0
|
2
|
4
|
5
|
6
|
7
|
5
|
6
|
7
|
|
Net Income (Common) |
69
N/A
|
97
+41%
|
129
+34%
|
150
+17%
|
168
+12%
|
171
+2%
|
194
+13%
|
203
+5%
|
230
+13%
|
233
+1%
|
252
+8%
|
273
+8%
|
|
EPS (Diluted) |
0.7
N/A
|
1.08
+54%
|
1.22
+13%
|
1.43
+17%
|
1.6
+12%
|
1.63
+2%
|
1.84
+13%
|
1.93
+5%
|
2.18
+13%
|
2.21
+1%
|
2.4
+9%
|
2.59
+8%
|